Acute Subcutaneous SemaglutidE in Acute Ischemic sTroke

PHASE2RecruitingINTERVENTIONAL
Enrollment

380

Participants

Timeline

Start Date

April 12, 2023

Primary Completion Date

September 30, 2025

Study Completion Date

December 31, 2027

Conditions
Acute Ischemic Stroke
Interventions
DRUG

Semaglutide

Subcutaneous Semaglutide, 0.5 mg weekly for 4 weeks. First dose given at inclusion.

OTHER

Standard care

Treatment according to Danish national clinical guidelines on stroke treatment, including reperfusion therapy if eligible.

Trial Locations (1)

8000

RECRUITING

Aarhus University Hospital, Aarhus

All Listed Sponsors
collaborator

Bispebjerg Hospital

OTHER

collaborator

Glostrup University Hospital, Copenhagen

OTHER

collaborator

Odense University Hospital

OTHER

collaborator

Herning Hospital

OTHER

collaborator

Aalborg University Hospital

OTHER

collaborator

Rigshospitalet, Denmark

OTHER

lead

Aarhus University Hospital

OTHER

NCT05630586 - Acute Subcutaneous SemaglutidE in Acute Ischemic sTroke | Biotech Hunter | Biotech Hunter